WO2000045800A3 - Effets immunosuppresseurs des derives de pteridine - Google Patents

Effets immunosuppresseurs des derives de pteridine Download PDF

Info

Publication number
WO2000045800A3
WO2000045800A3 PCT/EP2000/000938 EP0000938W WO0045800A3 WO 2000045800 A3 WO2000045800 A3 WO 2000045800A3 EP 0000938 W EP0000938 W EP 0000938W WO 0045800 A3 WO0045800 A3 WO 0045800A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosurpressive
effects
pteridine derivatives
treatment
pteridine
Prior art date
Application number
PCT/EP2000/000938
Other languages
English (en)
Other versions
WO2000045800A2 (fr
Inventor
Mark Jozef Albert Waer
Piet Andre Maurits M Herdewijn
Wolfgang Eugen Pfleiderer
Original Assignee
Leuven K U Res & Dev
Mark Jozef Albert Waer
Piet Andre Maurits M Herdewijn
Wolfgang Eugen Pfleiderer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven K U Res & Dev, Mark Jozef Albert Waer, Piet Andre Maurits M Herdewijn, Wolfgang Eugen Pfleiderer filed Critical Leuven K U Res & Dev
Priority to AU24418/00A priority Critical patent/AU780284B2/en
Priority to CA002361561A priority patent/CA2361561A1/fr
Priority to EP00902660A priority patent/EP1187615A2/fr
Priority to JP2000596920A priority patent/JP2002536320A/ja
Publication of WO2000045800A2 publication Critical patent/WO2000045800A2/fr
Publication of WO2000045800A3 publication Critical patent/WO2000045800A3/fr
Priority to US10/444,158 priority patent/US6946465B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour le traitement de troubles auto-immuns et/ou pour le traitement ou la prévention de rejets de greffes comprenant un dérivé de ptéridine de formule générale (I), particulièrement une lumazine, éventuellement combinée à un second agent actif.
PCT/EP2000/000938 1999-02-02 2000-02-02 Effets immunosuppresseurs des derives de pteridine WO2000045800A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU24418/00A AU780284B2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives
CA002361561A CA2361561A1 (fr) 1999-02-02 2000-02-02 Effets immunosuppresseurs des derives de pteridine
EP00902660A EP1187615A2 (fr) 1999-02-02 2000-02-02 Effets immunosuppresseurs des derives de pteridine
JP2000596920A JP2002536320A (ja) 1999-02-02 2000-02-02 プテリジン誘導体の免疫抑制作用
US10/444,158 US6946465B2 (en) 1999-02-02 2003-05-23 Immunosuppressive effects of pteridine derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11823599P 1999-02-02 1999-02-02
US11829599P 1999-02-02 1999-02-02
US11828299P 1999-02-02 1999-02-02
US60/118,235 1999-02-02
US60/118,295 1999-02-02
US60/118,282 1999-02-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09890500 A-371-Of-International 2001-10-30
US10/444,158 Continuation-In-Part US6946465B2 (en) 1999-02-02 2003-05-23 Immunosuppressive effects of pteridine derivatives

Publications (2)

Publication Number Publication Date
WO2000045800A2 WO2000045800A2 (fr) 2000-08-10
WO2000045800A3 true WO2000045800A3 (fr) 2002-01-10

Family

ID=27382128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000938 WO2000045800A2 (fr) 1999-02-02 2000-02-02 Effets immunosuppresseurs des derives de pteridine

Country Status (5)

Country Link
EP (1) EP1187615A2 (fr)
JP (1) JP2002536320A (fr)
AU (1) AU780284B2 (fr)
CA (1) CA2361561A1 (fr)
WO (1) WO2000045800A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
MXPA02007868A (es) 2000-02-16 2003-02-10 Neurogen Corp Arilpirazinas sustituidas.
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
CA2496197A1 (fr) 2002-08-20 2004-03-04 Neurogen Corporation 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
CA2548172A1 (fr) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines utiles comme inhibiteurs des proteines kinases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
EP2297106B1 (fr) 2008-05-27 2014-07-16 AstraZeneca AB Dérivés de phénoxypyridinylamide et leur utilisation dans le traitement d'états pathologiques induits par la phosphodiésterase 4 (pde4)
WO2016118823A1 (fr) * 2015-01-22 2016-07-28 The Scripps Research Institute Inhibiteurs ptéridine dione du transporteur de monocarboxylate
CN107108615B (zh) 2015-03-04 2020-11-20 吉利德科学公司 Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物
EP3507276B1 (fr) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Composés modulateurs du recepteur de type toll
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
AU2021299167B2 (en) * 2020-07-03 2024-03-21 Comvita Limited Anti-inflammatory compositions, methods and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011001A1 (fr) * 1992-11-16 1994-05-26 Cell Therapeutics, Inc. Composes a teneur hydroxyle
WO1994022449A1 (fr) * 1993-04-05 1994-10-13 Cell Therapeutics, Inc. Composes therapeutiques
WO1995013075A1 (fr) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
WO1995031469A1 (fr) * 1994-05-18 1995-11-23 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Analogues de nucleotides de pteridine sous forme d'echantillons d'adn fluorescents
WO1996010568A1 (fr) * 1994-09-30 1996-04-11 Merck & Co., Inc. Piperazines a substitution aryle antagonistes de la neurokinine
WO1996020710A1 (fr) * 1994-12-29 1996-07-11 The Regents Of The University Of California Composes permettant d'inhiber la transduction des signaux a mediation par la ceramide
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
WO1998052948A1 (fr) * 1997-05-19 1998-11-26 The Regents Of The University Of California Composes pour l'inhibition de la transduction de signaux a mediation ceramide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
WO1993025712A1 (fr) * 1992-06-15 1993-12-23 The Regents Of The University Of California Test de triage pour l'identification de medicaments immunosuppresseurs
WO1994014065A1 (fr) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Procedes d'identification et d'utilisation de composes immunodeprimants
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
AU2666997A (en) * 1996-04-15 1997-11-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The In vitro prognostic test for progressors and non-progressors after hiv infection

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011001A1 (fr) * 1992-11-16 1994-05-26 Cell Therapeutics, Inc. Composes a teneur hydroxyle
WO1994022449A1 (fr) * 1993-04-05 1994-10-13 Cell Therapeutics, Inc. Composes therapeutiques
WO1995013075A1 (fr) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
WO1995031469A1 (fr) * 1994-05-18 1995-11-23 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Analogues de nucleotides de pteridine sous forme d'echantillons d'adn fluorescents
WO1996010568A1 (fr) * 1994-09-30 1996-04-11 Merck & Co., Inc. Piperazines a substitution aryle antagonistes de la neurokinine
WO1996020710A1 (fr) * 1994-12-29 1996-07-11 The Regents Of The University Of California Composes permettant d'inhiber la transduction des signaux a mediation par la ceramide
WO1998052948A1 (fr) * 1997-05-19 1998-11-26 The Regents Of The University Of California Composes pour l'inhibition de la transduction de signaux a mediation ceramide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUU-HOI, N. P. ET AL: "Phthalonimides (1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolines) of potential biological interest", J. HETEROCYCL. CHEM., vol. 5, no. 4, 1968, pages 545 - 547, XP000906859 *
COTTAM ET AL: "Substituted Xanthines, Pteridinediones, and Related Compounds as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor-alpha", J. MED. CHEM., vol. 39, no. 1, 1996, pages 2 - 9, XP000906858 *

Also Published As

Publication number Publication date
WO2000045800A2 (fr) 2000-08-10
AU2441800A (en) 2000-08-25
CA2361561A1 (fr) 2000-08-10
AU780284B2 (en) 2005-03-10
JP2002536320A (ja) 2002-10-29
EP1187615A2 (fr) 2002-03-20

Similar Documents

Publication Publication Date Title
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
BG106030A (en) Pharmaceutical composition
CA2392879A1 (fr) Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
WO2003013541A8 (fr) Derives de la 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine
WO2001062737A3 (fr) Derives d'amino pyrazole utilises dans le traitement de l'obesite et d'autres troubles
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO2004005286A3 (fr) Inhibiteurs viraux
CA2294913A1 (fr) Composition pharmaceutique presentant une activite antitumorale amelioree et/ou des effets secondaires reduits contenant un agent antitumoral et un derive d'acide hydroximique
EP1259240B8 (fr) Agents de traitement des troubles cutanés, tel le nicotinamide et le cADPR
WO2001035950A3 (fr) Agent therapeutique a base d'amide et procedes de traitement des affections intestinales inflammatoires
MXPA03010761A (es) Combinaciones farmaceuticas.
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
PL346764A1 (en) New oral formulation for 5-ht4
CA2368165A1 (fr) Sels de carboxamide d'aminoimidazole utiles dans la prevention et le traitement des maladies du foie
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
CA2340734A1 (fr) Derive de pyridyl-4h-1,2,4-oxadiazine optiquement actif et son utilisation dans le traitement des maladies vasculaires
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
WO2002080978A3 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2361561

Country of ref document: CA

Ref country code: CA

Ref document number: 2361561

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 24418/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 596920

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000902660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09890500

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000902660

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 24418/00

Country of ref document: AU